OFIX — Orthofix Medical Inc.

Orthofix Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Total Global Net Sales: $203.4 million, a 6% increase year-over-year.
• U.S. Spine Fixation Sales: Increased 8% with procedural volume up 10%.
• Adjusted Gross Margin: 72.1%, up 80 basis points from Q3 2024.
• Adjusted EBITDA: $24.6 million, representing 12.1% of net sales, with a 230 basis point year-over-year margin expansion.
• Free Cash Flow: Positive at $2.5 million, ending with $65.9 million in total cash.
• 2025 Full-Year Guidance: Pro forma net sales guidance narrowed to $810 million to $814 million; adjusted EBITDA guidance raised to $84 million to $86 million.

2. Strategic Updates and Business Highlights:

• Continued strong performance in U.S. Spine and Orthopedics, with notable growth driven by the adoption of the 7D FLASH navigation system and the launch of new products such as the TrueLok Elevate and the FITBONE Bone Transport nail.
• The new VIRATA Spinal Fixation system is in limited market release, expected to drive growth post-launch in 2026.
• Successful distributor transitions have led to a 25% year-over-year sales increase among the top 30 U.S. distributor partners.
• The Bone Growth Therapies segment achieved 6% growth, outperforming the market.

3. Forward Guidance and Outlook:

• The company expects continued momentum in the Spine, Bone Growth Therapies, and Orthopedics segments, with a focus on disciplined profitable growth and positive free cash flow generation.
• Anticipated gross margins for the second half of 2025 are approximately 72%.
• The company plans to provide formal 2026 guidance during the Q4 call in February 2026.

4. Bad News, Challenges, or Points of Concern:

• The company is facing a challenging comparison for Q4 due to strong performance in the same quarter last year, leading to an implied revenue deceleration to about 4% growth.
• There are ongoing price pressures in some major accounts, which may impact future sales performance.
• The discontinuation of the M6 artificial disc product lines continues to affect revenue metrics.

5. Notable Q&A Insights:

• Management emphasized that the strong growth in U.S. Spine is driven by successful distributor transitions and the innovative 7D FLASH technology.
• There is optimism about the potential for additional studies validating the TrueLok Elevate, which could enhance its market position.
• The company is focused on consolidating and expanding its distributor network to enhance market penetration, which is expected to yield benefits in 2026 and beyond.

Overall, Orthofix demonstrated solid financial performance in Q3 2025, supported by strategic initiatives and product innovation, while also navigating challenges related to market comparisons and pricing pressures.